Staff Profile

Qualifications

• BSc (Hons), Biomedical Sciences, Northumbria University.
• PhD, Newcastle University.

Administrative responsibilities

• Member of the executive board of Northern Institute for Cancer Research
• RA representative to senior staff meetings.
• Lab tissue culture co-ordinator
• Establishing and running Imagestream/CTC research group.

Membership

• British Association of Cancer Research

Research interests

• Investigation, development and validation of biomarkers for pharmacodynamic endpoints in early phase clinical trials.
• Establishment of methods to detect circulating tumour cells.
• Imaging flow cytometry and quantitative image analysis.
• Pharmacogenetics.

Grants received

• Lead by J. Llovet on behalf of the THRIVE consortium. Tumour-host interactions in liver cancer of childhood and adults. EU Horizon MISS 2023. Autumn 2023 to autumn 2028. €11,995,060.5 awarded (of which €1,380,141.25 allocated to Newcastle University & €218,216.25 allocated to The Newcastle upon Tyne Hospitals NHS Foundation Trust)
• H. Reeves, D Jamieson R, Shukla. Identification of ‘liquid biopsy’ predictive biomarkers in patients with advanced hepatocellular carcinoma. The Alice Stephenson Bequest PhD studentship. September 2022 to September 2025.
• H. Reeves, D Palmer, S Wedge, D Jamieson R, Shukla. Liver Cancer – Developing DNA-PK as a predictive biomarker and clinical target. MRC DiMeN DTP studentships. September 2021 to September 2024.
• D Jamieson. CTC, IHC and Nanostring pharmacodynamic assays for MIV-818 phase I trial. Medivir. August 2018 to July 2021. £269,572 awarded.
• D Jamieson. AZD3965 - A monocarboxylate transporter 1 inhibitor in patients with advanced cancer. CRUK. February 2018 to February 2020. £16,424 awarded
• AP Greystoke, D Jamieson, GJ Veal. PD Biomarkers Centre of Excellence. CDD. May 2017 to May 2019. £137,600 awarded
• DA Tweddle, L Chen, D Jamieson. Understanding neuroblastoma heterogeneity: Genetic studies of circulating neuroblastoma tumour cells. CCLG December 2016 to November 2017. £37,875.14 awarded.
• AP Greystoke, D Jamieson, GJ Veal, SR Wedge. MOv18 Phase I Study. CRUK. October 2015 to October 2018. £13,860.00 awarded. 
• AP Greystoke, D Jamieson, GJ Veal. LY314921 SUA PD Biomarker. CRUK. July 2016 to July 2017. £29,077.31 awarded.
• AP Greystoke, D Jamieson, GJ Veal. A pilot project to investigate the added utility of circulating miRNAs in distinguishing between response and toxicity in patients with primary brain tumours treated with chemoradiotherapy. JGWP. September 2016 to July 2018. £41,139.11 awarded.
• D Jamieson. CTC pharmacodynamic assay for C/EBPa saRNA phase I trial. MINA Alpha Limited. July 2016 to March 2019. £46,368 awarded.
• GJ Veal, Jamieson D. Pharmacogenetics of Doxorubicin, Gemcitabine and Docetaxel in Patients studied on the GeDDiS trial (Sarcoma). Sarcoma UK. August 2015 to August 2016. £22,317.16 awarded.
• UK Mallick, V Paleri, GJ Veal, P Perros, TWJ Lennard, ER Plummer, D Jamieson. Feasibility of detection and enumeration of Circulating Tumour Cells in Thyroid Cancer using the Veridex LLC (Cell-Search) and the ImageStreamX Mark II (Amnis) flow cytometry methods – A Newcastle-Manchester joint pilot study. Newcastle Healthcare Charity. December 2014 to December 2015. £30,479.80 awarded.
• Boddy AV, Jamieson D, Dean J. Welcome Trust Biomedical Vacation Scholarship. June to July 2013. £1,440 awarded.
• FEB May, D Jamieson, SM Griffin. Prognostic, predictive and pharmacodynamic value of circulating tumour cells in oesophagogastric cancer patients in receipt of palliative systemic therapy. JGWP. November 2013 to December 2015. £46,136 awarded.
• D Jamieson, AV Boddy, R Plummer, N Curtain, H Reeves, R Edmondson, C Robson, FEB May: Development of CTC assays. NICR Pump Priming funds. April 2012 to April 2013. £90,000 awarded.
• D Jamieson, AV Boddy, R Plummer: Capital costs for purchase of ImageStreamX imaging flow cytometer. Bobby Robson Foundation. 2012, £420,000 awarded.
• D Jamieson, FEB May, AV Boddy: Application to JGWP for consumable money to investigate NQO2 in kinase mediated signalling in breast cancer – 2008 to 2009, £16, 561 awarded.
• AV Boddy, D Jamieson, KKN Chan: Relationship between genotype and reductase enzyme activity in bladder and ovarian tumours. Nuffield Science Bursaries Undergraduate Research. July 2007-August 2007. £1,360 awarded.
• D Jamieson & HY Leung: Establishment of a high throughput screen for modifiers of apoptosis and cell cycle kinetics in a metastatic prostate cancer cell line for drug and drug target discovery. Newcastle NHS Special Trustees, project grant. July 2006-June 2007. £47,000 awarded.

Teaching responsibilities

• Undergraduate lecture on the use of alkylating agents in cancer chemotherapy.
• Joint module leader on Oncology and Palliative Care MSc: Pharmacology of Anticancer Drugs
• Supervision of undergraduates, masters and PhD students.

• Articles

  • Gulati P, Carruthers V, Hutton C, Cassidy C, Amankwatia EB, Pascual S, Florence E, Gebru TG, Jorgensen AL, Greystoke A, Makin G, McCabe MG, Hawcutt DB, Veal GJ, Jamieson D. An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma. EJC Paediatric Oncology 2025, 5, 100216.
  • Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, Veal GJ. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology 2023, 92, 325–328.
  • Idowu OS, Craigen JL, Veal GJ, Jamieson D. Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum. Bioanalysis 2022, 14(18), 1241-1249.
  • Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population. Pharmaceuticals 2021, 14(3), 272.
  • Doan M, Case M, Masic D, Hennig H, McQuin C, Caicedo J, Singh S, Goodman A, Wolkenhauer O, Summers H, Jamieson D, van Delft FW, Filby A, Carpenter A, Rees P, Irving J. Label-Free Leukemia Monitoring by Computer Vision. Cytometry A 2020, 97(4), 407-414.
  • Hellmann F, Völler S, Krischke M, Jamieson D, André N, Bisogno G, Boddy A, Hempel G. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial. European Journal of Drug Metabolism and Pharmacokinetics 2020. In Preparation.
  • Merugu S, Chen L, Gavens E, Gabra H, Brougham M, Makin G, Ng A, Murphy D, Gabriel AS, Robinson ML, Wright JH, Burchill SA, Humphreys A, Bown N, Jamieson D, Tweddle DA. Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers. Clinical Cancer Research 2020, 26(1), 122-134.
  • Uitrakul S, Hutton C, Veal GJ, Jamieson D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. European Journal of Clinical Investigation 2019, 49(7), e13115.
  • Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. British Journal of Cancer 2018, 118, 248-257.
  • Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
  • Ribeiro R, Pal D, Jamieson D, Rankin K, Benning M, Dalgarno K, Ferreira A. Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer. ACS Applied Materials & Interfaces 2017, 9(15), 12967-12974.
  • Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European Journal of Cancer 2017, 71, 15-24.
  • Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marple M, Veal G, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi H, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncology 2017, 18(10), 1397-1410.
  • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer 2016, 114(7), 723-730.
  • Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NC, Jamieson D, Reeves HL. Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology 2016, 65(2), 305-313.
  • Dent BM, Ogle LF, O'Donnell RL, Hayes N, Mallick U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FEB, Jamieson D. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer 2016, 138(1), 206-216.
  • Cresti N, Lee J, Rourke E, Televantou D, Jamieson D, Verrill M, Boddy AV. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance. European Journal of Cancer 2016, 55, 27-37.
  • Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. European Journal of Cancer 2016, 55, 56–64.
  • Woodward J, Taylor GC, Soares DC, Boyle S, Sie D, Read D, Chathoth K, Vukovic M, Tarrats N, Jamieson D, Campbell KJ, Blyth K, Acosta JC, Ylstra B, Arends MJ, Kranc KR, Jackson AP, Bickmore WA, Wood AJ. Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability. Genes & Development 2016, 30, 2173-2186.
  • Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer 2016, 68, 1-10.
  • Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemotherapy and Pharmacology 2014, 74(4), 667-674.
  • Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochemical Pharmacology 2014, 88(1), 58-65.
  • Hill CR, Jamieson D, Thomas HD, Brown CDA, Boddy AV, Veal GJ. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology 2013, 85(1), 29-37.
  • Armstrong JL, Martin S, Illingworth NA, Jamieson D, Neilson A, Lovat PE, Redfern CPF, Veal GJ. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncology Reports 2012, 27(1), 293-298.
  • Daly AK, Veal GJ, Jamieson D, Coulthard S. Pharmacogenomics research at Newcastle University. Pharmacogenomics 2012, 13(12), 1333-1338.
  • Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.
  • Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, Lloyd JL, Wipat A, Reynolds NJ. Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation. Journal of Investigative Dermatology 2011, 131(9), 1916-1926.
  • Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Cancer 2010, 102(6), 1003-1009.
  • Jamieson D, Cresti N, Verrill MW, Boddy AV. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of Immunological Methods 2009, 345(1-2), 106-111.
  • Jamieson D, Wilson K, Pridgeon S, Margetts J, Edmondson R, Leung H, Knox R, Boddy AV. NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clinical Cancer Research 2007, 13(5), 1584-1590.
  • Jamieson, D., Tung, A., Knox, R., Boddy, A. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. British Journal of Cancer 2006, 95(9), 1229-1233.

• Book Chapter

  • Jamieson D. Mitomycin C. In: Schwab, M, ed. Encyclopedia of Cancer. Berlin: Springer-Verlag, 2008.

• Conference Proceedings (inc. Abstracts)

  • Macheka S, Jamieson D, Reeves H, McCain M. The isolation and characterisation of circulating tumour cells from patients with hepatocellular carcinoma. In: 6th Christie International Student Cancer Conference. 2016, Manchester: International Institute of Anticancer Research.
  • Greystoke A, Hogarth L, Patterson M, Williams I, Ness T, Georgiadis K, Bolt L, Bettison I, Turner D, Jamieson D, Simmons T, Hughes A, Jaedicke K, Gardiner J, Mulvenna P, Leaning D, Bradshaw A, Butler R, Black F. The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier.
  • Wright JH, Humphreys A, Gabriel AS, Bown N, Chen L, Jamieson D, Tweddle DA. Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines. In: 48th Annual Congress of the International Society of Paediatric Oncology (SIOP). 2016, Dublin, Ireland: Wiley Periodicals, Inc.
  • Wyatt N, Hogarth L, Turner D, Patterson M, Jamieson D, Black F, Hutton C, Mulvenna P, Simmons T, Bradshaw A, Kolenda C, Parker C, Martin-Ruiz C, Greystoke A. Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). In: IASLC 17th World Conference on Lung Cancer. 2016, Vienna, Austria: Elsevier.
  • Ogle L, Jamieson D, O'Donnell R, Dent B, Boddy A, Curtin N, Plummer R, Reeves H, Clinical and Translational Group. Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x. In: The International Liver Congress 2014: 49th Annual Meeting of the European Association for the Study of the Liver. 2014, London: Elsevier BV.
  • Dent B, O'Donnell RL, Ogle LF, Rourke ED, Ramesh HP, Moat M, Hayes N, Mallick UK, May FE, Reeves HL, Curtain NJ, Edmondson RJ, Boddy AV, Plummer R, Jamieson D. Detection and characterization of circulating tumor cells by imaging flow cytometry. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
  • Mould E, Berry P, Jamieson D, Hill C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells. In: American Association for Cancer Research 104th Annual Meeting. 2013, Washington, DC, USA: American Association for Cancer Research.
  • Moat M, ODonnell R, Dent B, Ogle L, Curtin NJ, Jamieson D, Edmondson RJ. The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream. In: 18th International Meeting of the European Society of Gynaecological Oncology (ESGO). 2013, Liverpool, UK: Lippincott Williams & Wilkins.
  • Boddy AV, Cresti N, Jamieson D, Pinkilgton M, Verrill MW. Single nucleotide polymorphisms and expression/amplification of HER2 in patients with breast cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2011, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Cresti N, Jamieson D, Verrill MW, Pinkilgton M, Boddy AV. Fc gamma-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab. In: JOURNAL OF CLINICAL ONCOLOGY. 2011, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Weatherhead S, Farr P, Swan D, Jamieson D, Hallinan J, Lloyd J, Wipat A, Reynolds N. Apoptosis of keratinocytes is a key mechanism in UVB-induced clearance of psoriasis. In: 41st Annual Meeting of the European Society for Dermatological Research. 2011, Barcelona, Spain: Nature Publishing Group.
  • Weatherhead SC, Jamieson D, Reynolds NJ. Real-time imaging of ultraviolet B-induced keratinocyte apoptosis to determine duration of apoptosis and effect on tissue turnover. In: British Journal of Dermatology: Annual Meeting of the British Society for Investigative Dermatology. 2009, Royal Agricultural College, Cirencester, UK: Wiley-Blackwell.
  • Weatherhead SC, Jamieson D, Reynolds NJ. Real time imaging of UVB-induced keratinocyte apoptosis, and analysis of factors influencing cell-to-cell variation. In: Journal of Investigative Dermatology: 39th Annual Meeting of the European Society for Dermatological Research (ESDR). 2009, Budapest, Hungary: Nature Publishing Group.

• Reviews

  • Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism and Toxicology 2011, 7(10), 1201-1210.
  • Cresti N, Jamieson D. The pharmacology of trastuzumab and its use in breast cancer. Clinical Medicine Reviews in Oncology 2010, 2, 149-165.